Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Invimestrocel · HLCM-051

Cell therapy (Stem-cell derived) · Cell replacement · developed by Healios K.K.

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Invimestrocel?

Invimestrocel is an allogeneic cell therapy consisting of multipotent adult progenitor cells (MAPCs) derived from bone marrow and expanded for off-the-shelf use. The non-immunogenic cells are designed to restore immune function and produce therapeutic molecules in response to inflammation and tissue damage. It is studied in ischemic stroke.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HLCM-051, MultiStem
Drug type
Cell therapy (Stem-cell derived)
Mechanism
Cell replacement
Pathways
hematopoiesis, immunomodulation
Therapy area
Neurology
Developer
Healios K.K.
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WNR9FH307P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03545607 Phase 3 Ischemic Stroke Terminated MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ischemic Stroke

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.